; and (4) provide the results of the analysis, assessment, and strategy developed under this subsection to the Federal Acquisition Regulatory Council and the appropriate congressional committees. (i) Report requirement (1) In general Not later than 180 days after the date of the enactment of this Act, the Federal entity shall submit to the Federal Acquisition Regulatory Council and the appropriate congressional committees a report including the following: (A) The name of and justification for each entity meeting the criteria for a biotechnology company of concern under subsections (f)(1) and (g). (B) A catalog of all active or planned grants or contracts any Executive agency has with any entity determined to be a biotechnology company of concern related to biotechnology equipment or services. (C) Recommendations, as applicable, on alternative entities to a biotechnology company of concern capable of providing the Federal Government with required biotechnology equipment or services. (D) Recommendations, as applicable, on the feasibility of implementing prohibitions implemented in connection with the guidance established under subsection (b) or exercising waiver authorities under subsection (e), to ensure uninterrupted Federal Government access to required biotechnology equipment and services, and any further changes to legislation needed to mitigate supply chain risks or increase availability and enhance capabilities of biotechnology equipment and services. (2) Form The report required under paragraph (1) shall be in unclassified form accompanied by a classified annex. (j) Definitions In this section: (1) Appropriate congressional committees The term appropriate congressional committees means— (A) the Committee on Armed Services, the Committee on Commerce, Science, and Transportation, the Committee on Foreign Relations, the Committee on Health, Education, Labor, and Pensions, and the Committee on Homeland Security and Governmental Affairs of the Senate